Cephalalgia

Papers
(The TQCC of Cephalalgia is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care109
Harassment in the headache field: a global web-based cross-sectional survey86
A reply, drug-induced reversible cerebral vasoconstriction syndrome: Lessons from the real world75
International Classification of Headache Disorders-4 – Work in Progress 175
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response67
High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients61
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials60
Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controll59
Evidence-based guidelines for the pharmacological treatment of migraine56
Population-based prevalence of cranial autonomic symptoms in migraine and proposed diagnostic appendix criteria54
Depression screening in migraine - A double-edged sword53
Assessing migraine therapeutics50
Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization48
Comment on “What predicts citation counts and translational impact in headache research? A machine learning analysis”43
Call for papers42
Corrigendum to: Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex41
Systemic lupus erythematosus mimicking retinal migraine: a case report39
Diagnosis of idiopathic intracranial hypertension - the importance of excluding secondary causes: A systematic review39
The effects of certain TRP channels and voltage-gated KCNQ/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system38
Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury37
Letter to the editor regarding “Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database”35
An altered reward system characterizes chronic migraine with medication overuse headache34
Pain sensitivities predict prophylactic treatment outcomes of flunarizine in chronic migraine patients: A prospective study32
Childhood and adolescent headache: A problem not to be ignored in the era of new therapies31
Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment30
Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study30
CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis29
Effect of Altmetric score on manuscript citations: A randomized-controlled trial28
Galcanezumab modulates Capsaicin-induced C-fiber reactivity27
History of maternal migraine and its association with preeclampsia: A case–control study in a low-resource setting in Sudan, Africa27
What is the evolutionary disadvantage of migraine?27
Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients27
COVID-19 vaccination-triggered cluster headache episodes with frequent attacks27
Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?27
Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study26
Sensitivity of the SNNOOP10 list in the high-risk secondary headache detection26
Migraine and risk of atrial fibrillation: A 9-year follow-up based on the Trøndelag Health Study26
Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine25
Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions25
Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1st edition24
A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants24
Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks24
Author response to ‘Clarification on the incidence and sex-specificity of sexual dysfunction as an adverse event of CGRP-targeting medications’23
Sex differences in photophobic behaviors following cortical spreading depression in rats23
Comorbidity or combination – more evidence for cluster-migraine?23
The midfacial segment pain: little known disorder in need of scientific evaluation23
Looking at Cephalalgia from the inside22
Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®22
Crossing the Rubicon? The future impact of artificial intelligence on headache medicine22
Guidelines Update: Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition – An experience-based update22
The non-decussating and decussating trigeminothalamic tracts in humans: A combination of connectome-based tractography and histological validation22
Clinical, oculographic, and vestibular test characteristics of vestibular migraine21
Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies21
Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks21
Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significance20
Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review19
Muscae volitantes: A 19th-century precursor of visual snow syndrome?19
The “index vein” as a sign for migraine aura in the emergency setting19
Abstracts from the International Headache Congress 14–17 September 202318
Poor social support and loneliness in chronic headache: Prevalence and effect modifiers17
Burden of headache in a HIV-positive population of sub-Saharan Africa17
Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: An exploratory study17
Psychophysical testing in chronic migraine and chronic tension type headache: An observational study17
Thanks to Reviewers17
Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society17
Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process17
Premonitory symptoms in migraine: A REFORM Study16
Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study16
Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent he16
Exploring the association between familial hemiplegic migraine genes (CACNA1A, ATP1A2 and SCN1A) with migraine and epilepsy: A UK Biobank exome-wide association study16
The impact of eating disorders on idiopathic intracranial hypertension16
Letter to the Editor regarding “Effect of Altmetric score on manuscript citations: A randomized-controlled trial”16
Stroke due to small-vessel disease and migraine: A case–control study of a young adult with ischemic stroke population16
Are we closer to achieving precision medicine for migraine treatment? A narrative review16
Erratum16
Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society16
Shared genetics and causal relationships between migraine and thyroid function traits15
Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache15
Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives15
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach15
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients15
Are the ICHD-3 criteria for headache attributed to idiopathic intracranial hypertension valid? Headache phenotyping and field-testing in newly diagnosed idiopathic intracranial hypertension15
Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days15
Corneal confocal microscopy identifies corneal nerve fiber loss in patients with migraine15
Internet and social media's role in migraine education: Headache or not headache?15
New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication14
Corrigendum: No structural brain alterations in new daily persistent headache – a cross sectional VBM/SBM study14
BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm14
Headache at the chronic stage of cerebral venous thrombosis14
Cigarette smoking history (personal and secondary childhood exposure) in non-cluster headache trigeminal autonomic cephalalgias: A clinic based study14
Board Walk – April 202214
Recurrent Painful Ophthalmoplegic Neuropathy: A case report with atypical features and a review of the literature14
Postprandial fasting related headache during Ramadan in Saudi Arabia: A cross-sectional study14
The long-term effect of work schedule, shift work disorder, insomnia and restless legs syndrome on headache among nurses: A prospective longitudinal cohort study14
Bridging the gaps of headache care for underserved populations: Current status of the headache field in Latin America13
Electrophysiological findings in migraine may reflect abnormal synaptic plasticity mechanisms: A narrative review13
Prevalence and treatment of typical and atypical headaches in patients with Chiari I malformation: A meta-analysis and literature review13
Hypnic Headache – What do we know in 2022?13
Children under 6 years with acute headache in Pediatric Emergency Departments. A 2-year retrospective exploratory multicenter Italian study13
Reply to “Methodological considerations in assessing the impact of CGRP monoclonal antibodies on blood pressure”13
Comparison of continuous headache features in youth with migraine, new daily persistent headache, and persistent post-traumatic headache13
Longitudinal trajectories of posttraumatic headache after pediatric mild traumatic brain injury13
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study13
Avoidance behaviour modulates but does not condition phonophobia in migraine13
Comment on “Lack of reproducibility of resting-state functional MRI findings in migraine with aura”13
“Wearing-off” efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials13
Proposed general diagnostic criteria for secondary headaches13
Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-1912
Other primary headaches: Distinct clinical features and uncertain pathophysiology12
Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura12
Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models12
Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports12
Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial12
Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab12
Cephalalgia: a legacy of excellence, a vision for tomorrow12
Orofacial pain for clinicians: A review of constant and attack-like facial pain syndromes12
Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine12
Prevalence of neck pain in migraine: A systematic review and meta-analysis12
Late Breaking Author Index12
What do people want to know about “Growing Up with Migraine”? Results of a preference survey of people with lived experience to guide future research12
Response to letter to the Editor: Assessing migraine therapeutics11
Comment on ‘'Correlation between endometriosis and migraine features: Results from a prospective case-control study'‘11
Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review11
A need for an expert consensus guideline on performing peripheral nerve blocks in headache patients11
The first prevalence study of primary headaches in adults in a post-conflict area of Serbia11
Oxygen inhalation has no effect on provoked cranial autonomic symptoms using kinetic oscillation stimulation in healthy volunteers11
Epicranial headaches part 2: Nummular headache and epicrania fugax11
Personal view: Modelling pain mechanisms of migraine without aura10
Multidisciplinary headache treatment with work-focus in Norway: An observational study10
Measuring headache day severity using multiple features in daily diary designs10
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study10
Overuse of analgesics can affect the fertility biomarker Anti-Müllerian Hormone in females. A translational study10
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies10
Developing an artificial intelligence-based headache diagnostic model and its utility for non-specialists’ diagnostic accuracy10
Migraine and the risk of stroke in a middle-aged and elderly population: A prospective cohort study10
An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine10
How migraine and its associated treatment impact on pregnancy outcomes: Umbrella review with updated systematic review and meta-analysis10
Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review10
Headache provocation by nitric oxide in men who have never experienced a headache10
Persistent headache attributed to past cervicocephalic artery dissection: clinical characteristics and contributors to headache persistence10
Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study10
Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study10
Recovery and long-term outcome after neurosurgical closure of spinal CSF leaks in patients with spontaneous intracranial hypotension10
Primary headache disorders in adolescents in North- and South-Tyrol: Findings of the EVA-Tyrol-Study10
Treatment experiences and clinical characteristics in migraine and tension-type headache patients before the first visit to a tertiary headache center10
0.1496729850769